Althea Group Holdings Past Earnings Performance
Past criteria checks 0/6
Althea Group Holdings's earnings have been declining at an average annual rate of -10%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 47.4% per year.
Key information
-10.0%
Earnings growth rate
4.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 47.4% |
| Return on equity | -138.4% |
| Net Margin | -73.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Investors Continue Waiting On Sidelines For Althea Group Holdings Limited (ASX:AGH)
Feb 23
Althea Group Holdings Limited (ASX:AGH) Shares Fly 28% But Investors Aren't Buying For Growth
Apr 18We Think Althea Group Holdings (ASX:AGH) Needs To Drive Business Growth Carefully
Jul 11The Consensus EPS Estimates For Althea Group Holdings Limited (ASX:AGH) Just Fell A Lot
Feb 28Is Althea Group Holdings (ASX:AGH) In A Good Position To Invest In Growth?
Feb 25When Will Althea Group Holdings Limited (ASX:AGH) Become Profitable?
Mar 13Can You Imagine How Althea Group Holdings' (ASX:AGH) Shareholders Feel About The 28% Share Price Increase?
Feb 06
What You Need To Know About Althea Group Holdings Limited's (ASX:AGH) Investor Composition
Dec 04Revenue & Expenses BreakdownBeta
How Althea Group Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 29 | -21 | 24 | 0 |
| 30 Sep 23 | 27 | -17 | 24 | 0 |
| 30 Jun 23 | 25 | -14 | 24 | 0 |
| 31 Mar 23 | 24 | -14 | 23 | 0 |
| 31 Dec 22 | 23 | -14 | 21 | 0 |
| 30 Sep 22 | 22 | -13 | 20 | 0 |
| 30 Jun 22 | 21 | -12 | 19 | 0 |
| 31 Mar 22 | 18 | -13 | 20 | 0 |
| 31 Dec 21 | 16 | -14 | 20 | 0 |
| 30 Sep 21 | 14 | -14 | 20 | 0 |
| 30 Jun 21 | 12 | -15 | 19 | 0 |
| 31 Mar 21 | 10 | -15 | 17 | 0 |
| 31 Dec 20 | 8 | -15 | 15 | 0 |
| 30 Sep 20 | 7 | -15 | 15 | 0 |
| 30 Jun 20 | 5 | -15 | 14 | 0 |
| 31 Mar 20 | 4 | -15 | 14 | 0 |
| 31 Dec 19 | 2 | -15 | 14 | 0 |
| 30 Sep 19 | 2 | -12 | 11 | 0 |
| 30 Jun 19 | 1 | -9 | 9 | 0 |
| 31 Dec 18 | 0 | -4 | 4 | 0 |
| 30 Sep 18 | 0 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | -1 | 1 | 0 |
Quality Earnings: AGH is currently unprofitable.
Growing Profit Margin: AGH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGH is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare AGH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: AGH has a negative Return on Equity (-138.38%), as it is currently unprofitable.